Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia

X
Trial Profile

A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD-8233 (Primary) ; Ezetimibe; HMG-CoA reductase inhibitors
  • Indications Hyperlipidaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SOLANO
  • Sponsors AstraZeneca AB
  • Most Recent Events

    • 16 Oct 2022 This trial has been completed in Poland, according to European Clinical Trials Database record. (14 Jul 2022)
    • 22 Sep 2022 Primary endpoint (Percentage change from baseline on serum LDL-C) has been met, according to an Ionis Pharmaceuticals Media Release.
    • 22 Sep 2022 Results published in an Ionis Pharmaceuticals Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top